A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

STATUS

Recruiting
End date

Dec 30, 2024
participants needed

69
sponsor

Ascentage Pharma Group Inc.

Send

Updated on 4 October 2022

See if I qualify

myeloid leukemia

hydroxyurea

white blood cell count

chronic myelomonocytic leukemia

ejection fraction

immunosuppressive agents

cell transplantation

leukemia

azacitidine

refractory acute myeloid leukemia (aml)

acute promyelocytic leukemia

myelomonocytic leukemia

antifungal agents

Summary

This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will initially evaluate the safety and tolerability of APG-115 as a single agent in Part 1, followed by a combination of APG-115 + 5-azacitidine (5-AZA) in Part 2.

Description

Part 1: Dose escalation of APG-115 will use standard 3+3 design. APG-115 is administered orally once daily (QD) on Day 1-5 every 28-day cycle. The starting target dose is 100 mg (dose level; DL1) and will be increased in subsequent cohorts to 150 mg (DL2), 200 mg (DL3), and 250 mg (DL4), accordingly.

Part 2: Dose escalation of APG-115 in combination with 5-AZA will use standard 3+3 design. 5-AZA is administered at 75 mg/m˄2/d subcutaneously daily on Day 1-7 every 28 days.

Details

Condition	AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, CMML, Myelodysplastic Syndromes, High-risk Myelodysplastic Syndrome, MDS
Treatment	5-azacytidine, 5-azacitidine, APG-115
Clinical Study Identifier	NCT04358393
Sponsor	Ascentage Pharma Group Inc.
Last Modified on	4 October 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Patients with a diagnosis of histologically confirmed relapsed or refractory AML, CMML, or high-risk MDS (overall revised international prognostic scoring system (IPSS-R) score > 3, including intermediate, high, or very high risk) by World Health Organization (WHO) classification for which no available standard therapies are indicated or anticipated to result in a durable response
	Adequate organ function as defined below
	Liver function (total bilirubin < or = 1.5 x upper limit of normal (ULN), aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) <3 x ULN
	Kidney function (defined as a calculated creatinine clearance ≥ 60 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula)
	Known cardiac ejection fraction of > or = 45% within the past 3 months
	Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
	A negative serum pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial
	Patient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient or legally authorized representative is required prior to their enrollment on the protocol
	Subject must have a projected life expectancy of at least 12 weeks
	Subject has a white blood cell count < 25 × 10˄9/L. Note: Hydroxyurea is permitted to meet this criteria
	Exclusion
	Pregnant women are excluded
	Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure (NYHA Class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
	Have had leukemia therapy for 14 days prior to starting investigational drug. However, patients with rapidly proliferative disease may receive hydroxyurea as needed until 24 hours prior to starting therapy on this protocol and during the first cycle of study
	Have acute promyelocytic leukemia
	Active infection requiring systemic antibiotic/antifungal medication, known clinically active hepatitis B or C, or HIV infection
	Have received allogeneic hematopoietic stem cell transplant (HSCT) within 12 months prior to the first dose, or who have active/ongoing graft-versus host disease (GVHD), or require continued treatment with systemic immunosuppressive agents (calcineurin inhibitors within 4 weeks prior to the first dose), or received autologous hematopoietic stem cell transplantation within 6 months prior to the first dose
	Documented hypersensitivity to any of the components of the therapy program
	Active, uncontrolled central nervous system (CNS) leukemia will not be eligible
	Men and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use at least 1 form of barrier birth control (such as condom) prior to study entry and for the duration of study participation
	Any prior systemic MDM2-p53 inhibitor treatment
	Any other condition or circumstance that would, in the opinion of the investigator, make the patient unsuitable for participation in the study
	History of other malignancies within 2 years prior to study entry, with the exception
	of
	Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast
	Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin
	Previous malignancy confined and surgically resected (or treated with other modalities) with curative intention: requires discussion with sponsor
	Failure to have recovered (Grade > 1) from prior treatment (including chemotherapy
	targeted therapy, immunotherapy, experimental agents, radiation, or surgery)
	Significant screening electrocardiogram (ECG) abnormalities including left bundle branch block, 2nd degree atrioventricular (AV) block type II, 3rd degree block, or corrected QT interval (QTc) ≥470 msec

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

myeloid leukemia

hydroxyurea

white blood cell count

chronic myelomonocytic leukemia

ejection fraction

immunosuppressive agents

cell transplantation

leukemia

azacitidine

refractory acute myeloid leukemia (aml)

acute promyelocytic leukemia

myelomonocytic leukemia

antifungal agents

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS